Status:

ENROLLING_BY_INVITATION

Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma

Lead Sponsor:

Mayo Clinic

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Barrett Esophagus

Esophageal Adenocarcinoma

Eligibility:

All Genders

18-90 years

Brief Summary

This study explores the use of a minimally invasive screening tool (a sponge on a string device) to detect Barrett's esophagus and esophageal adenocarcinoma and to develop a laboratory test for the de...

Eligibility Criteria

Inclusion

  • Patient between the ages 18 - 90
  • Patients with a BE segment \>= 1cm in maximal extent endoscopically
  • Histology showing evidence of intestinal metaplasia with or without presence of dysplasia
  • Undergoing clinically indicated endoscopy

Exclusion

  • Patients with a prior history of ablation (photodynamic therapy, radiofrequency ablation, cryotherapy, argon plasma coagulation). Patients with a history of endoscopic mucosal resection alone will not be excluded
  • Patients with a history of esophageal or gastric resection for esophageal or gastric carcinoma
  • Subjects with or without known evidence of BE (on history or review of medical records)
  • Pregnant or lactating females
  • Patients who are unable to consent
  • Patients with a current history of uninvestigated dysphagia (this does not apply to the brushings only portion of the study)
  • History of eosinophilic esophagitis, achalasia
  • Patients on oral anticoagulation including Coumadin, and warfarin, unless discontinued for five days prior to the sponge procedure
  • Patients on antiplatelet agents including clopidogrel, unless discontinued for five days prior to the sponge procedure
  • Patients on oral thrombin inhibitors including dabigatran and oral factor X an inhibitor such as rivaroxaban, apixaban, and edoxaban, unless discontinued for five days prior to the sponge procedure
  • Patients with a history of known varices or cirrhosis
  • Patients with a history of esophageal or gastric resection
  • Patients with congenital or acquired bleeding diatheses
  • Patients with a history of esophageal squamous dysplasia

Key Trial Info

Start Date :

November 17 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

October 31 2028

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT07212491

Start Date

November 17 2025

End Date

October 31 2028

Last Update

December 31 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Mayo Clinic in Arizona

Scottsdale, Arizona, United States, 85259

2

Mayo Clinic in Florida

Jacksonville, Florida, United States, 32224-9980

3

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905